SCHEDULE: Nextech Entities Maintain 8.4% Stake in ORIC Pharma

Nextech Crossover I SCSp and related entities disclose continued beneficial ownership of 8.4% of ORIC Pharmaceuticals, Inc. common stock.

Summary

• Nextech Crossover I SCSp, Nextech Crossover I GP S.a. r.l., Ian Charoub, Costas Constantinides, and Rocco Sgobbo collectively reported beneficial ownership of 7,162,637 shares of ORIC Pharmaceuticals, Inc. common stock.
• This ownership represents 8.4% of the total class of securities outstanding.
• The percentage is based on 85,225,191 shares of common stock outstanding as of May 29, 2025, as reported in ORIC Pharmaceuticals' prospectus dated June 20, 2025.
• Nextech Crossover LP directly holds the shares, with Nextech Crossover GP serving as its sole general partner.
• Ian Charoub, Costas Constantinides, and Rocco Sgobbo are members of the board of managers of Nextech Crossover GP and possess power to direct the voting and disposition of the securities.
• The reporting persons expressly disclaim status as a 'group' for purposes of this Schedule 13G.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's operational or financial performance.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's operations or financial performance.

Industry Context

This Schedule 13G filing indicates a significant, continued investment by Nextech Crossover entities in ORIC Pharmaceuticals, a company operating in the pharmaceutical sector. Such disclosures are standard for institutional investors holding more than 5% of a public company's shares and provide transparency on major ownership stakes within the industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional ownership stake in the company, which can influence market perception and liquidity.

Key Dates

Keywords

ORIC Pharmaceuticals, Nextech Crossover, Beneficial Ownership, Common Stock, SEC Filing, Pharmaceuticals, Investment, Institutional Investor